open access

Vol 11, No 1 (2008)
Published online: 2008-01-15
Submitted: 2012-01-23
Get Citation

New forms of radionuclide therapy with 90Y in oncology

Alicja Hubalewska-Dydejczyk, Wojciech Jurczak, Anna Sowa-Staszczak, Jolanta Kunikowska, Leszek Królicki, Aleksandra Gilis-Januszewska, Agnieszka Giza, Magdalena Szurkowska, Dorota Pach, Bogusław Głowa, Renata Mikołajczak, Dariusz Pawlak, Agnieszka Stefańska, Bohdan Huszno, Aleksander B. Skotnicki
Nucl. Med. Rev 2008;11(1):5-11.

open access

Vol 11, No 1 (2008)
Published online: 2008-01-15
Submitted: 2012-01-23

Abstract


BACKGROUND: Currently, there is growing interest in the use of the beta emitter 90Y in systemic therapy in oncology. For successful therapy, an appropriate ligand is chosen to carry the isotope to the place of its action. As well as performing this function, the type of the ligand influences both the course and the side effects of the treatment. For RIT of lymphomas, bone marrow becomes the critical organ; in NET patients treated with labelled somatostatin analogues, increased kidney irradiation can occur. The aim of this study was to evaluate the side effects of therapy using 90Y associated with different ligands, depending on the charge to critical organs after treatment in two groups of patients: those with neuroendocrine tumours and those with non-Hodgkin's lymphomas.
MATERIAL AND METHODS: 32 patients with histopathologically confirmed NET treated with 90Y-DOTATATE (7.4 GBq/m2 cumulative dose) and 30 NHL patients treated with 90Y-ibritumomab tiuxetan (1200 MBq max dose) were enrolled in the study. The kidney function and changes of blood indices were assessed during the course of the therapy.
RESULTS: 59% of NET patients treated with 90Y-DOTATATE displayed transient reduction of blood indices, the largest after cycles III and IV of therapy. After 5 months an increase in creatinine level was noticed, but no statistically important changes in creatinine level and GFR were observed. In the group of patients with NHL, the change of haematological indices after RIT concerned mainly PLT, ANC and WBC. The reduction of the average PLT and WBC values started in the first weeks after the treatment application, reaching nadir in the 6th week and 8th week, respectively. No life threatening infections were observed in either group of patients.
CONCLUSIONS: After treatment with the use of the 90Y radionuclide, no significant treatment toxicity, including disorders involving the critical organs for both types of therapies, was found in the groups of neuroendocrine tumour and non-Hodgkin's lymphoma patients.

Abstract


BACKGROUND: Currently, there is growing interest in the use of the beta emitter 90Y in systemic therapy in oncology. For successful therapy, an appropriate ligand is chosen to carry the isotope to the place of its action. As well as performing this function, the type of the ligand influences both the course and the side effects of the treatment. For RIT of lymphomas, bone marrow becomes the critical organ; in NET patients treated with labelled somatostatin analogues, increased kidney irradiation can occur. The aim of this study was to evaluate the side effects of therapy using 90Y associated with different ligands, depending on the charge to critical organs after treatment in two groups of patients: those with neuroendocrine tumours and those with non-Hodgkin's lymphomas.
MATERIAL AND METHODS: 32 patients with histopathologically confirmed NET treated with 90Y-DOTATATE (7.4 GBq/m2 cumulative dose) and 30 NHL patients treated with 90Y-ibritumomab tiuxetan (1200 MBq max dose) were enrolled in the study. The kidney function and changes of blood indices were assessed during the course of the therapy.
RESULTS: 59% of NET patients treated with 90Y-DOTATATE displayed transient reduction of blood indices, the largest after cycles III and IV of therapy. After 5 months an increase in creatinine level was noticed, but no statistically important changes in creatinine level and GFR were observed. In the group of patients with NHL, the change of haematological indices after RIT concerned mainly PLT, ANC and WBC. The reduction of the average PLT and WBC values started in the first weeks after the treatment application, reaching nadir in the 6th week and 8th week, respectively. No life threatening infections were observed in either group of patients.
CONCLUSIONS: After treatment with the use of the 90Y radionuclide, no significant treatment toxicity, including disorders involving the critical organs for both types of therapies, was found in the groups of neuroendocrine tumour and non-Hodgkin's lymphoma patients.
Get Citation

Keywords

90Y-DOTA TATE; 90Y-ibritumomab tiuxetan; neuroendocrine tumours; non-Hodgkin' s lymphoma; radioimmunotherapy

About this article
Title

New forms of radionuclide therapy with 90Y in oncology

Journal

Nuclear Medicine Review

Issue

Vol 11, No 1 (2008)

Pages

5-11

Published online

2008-01-15

Bibliographic record

Nucl. Med. Rev 2008;11(1):5-11.

Keywords

90Y-DOTA TATE
90Y-ibritumomab tiuxetan
neuroendocrine tumours
non-Hodgkin's lymphoma
radioimmunotherapy

Authors

Alicja Hubalewska-Dydejczyk
Wojciech Jurczak
Anna Sowa-Staszczak
Jolanta Kunikowska
Leszek Królicki
Aleksandra Gilis-Januszewska
Agnieszka Giza
Magdalena Szurkowska
Dorota Pach
Bogusław Głowa
Renata Mikołajczak
Dariusz Pawlak
Agnieszka Stefańska
Bohdan Huszno
Aleksander B. Skotnicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl